In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions report...In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed.Moreover,independent high-risk factors for severe infusion reactions were assessed by the Chi-square test.The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old(71.05%)and primarily occurred within 10 min of drug administration(86.84%),and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide.Therefore,the patients with advanced age,previous history of drug allergy,basic medical history,and the first use of this drug,especially within 10 min after administration,should be highly vigilant and closely monitored.展开更多
BACKGROUND Atezolizumab is a programmed death ligand 1(PD-L1)inhibitor,and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma(HCC).Treatment with immu...BACKGROUND Atezolizumab is a programmed death ligand 1(PD-L1)inhibitor,and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma(HCC).Treatment with immune checkpoint inhibitors(ICIs)can lead to hypersensitivity reactions;however,anaphylactic shock is rare.We present a case of life-threatening anaphylactic shock during atezolizumab infusion and performed a relevant literature review.CASE SUMMARY A 75-year-old man was diagnosed with HCC recurrence after hepatectomy.He was administered immunotherapy with atezolizumab plus bevacizumab after an allergy to a programmed death-1(PD-1)inhibitor.The patient showed a sudden onset of dizziness,numbness,and lack of consciousness with severe hypotension during atezolizumab infusion.The treatment was stopped immediately.The patient’s symptoms resolved after 5 mg dexamethasone was administered.Because of repeated hypersensitivity reactions to ICIs,treatment was changed to oral targeted regorafenib therapy.CONCLUSION Further research is necessary for elucidating the hypersensitivity mechanisms and establishing standardized skin test and desensitization protocols associated with PD-1 and PD-L1 to ensure effective treatment with ICIs.展开更多
基金Guangzhou Municipal Science and Technology Bureau(Grant No.202102010186 and 202102010313).
文摘In recent years,the number of intravenous infusion reactions has been increasing with the wide application of mannatide in clinical practice.In the present study,38 cases of mannatide-induced infusion reactions reported in a single medical center from 2017 to 2021 were retrospectively analyzed.Moreover,independent high-risk factors for severe infusion reactions were assessed by the Chi-square test.The results showed that infusion reactions caused by mannatide mainly occurred in patients over 50 years old(71.05%)and primarily occurred within 10 min of drug administration(86.84%),and patients with underlying diseases or drug allergies suffered from severe infusion reactions caused by mannatide.Therefore,the patients with advanced age,previous history of drug allergy,basic medical history,and the first use of this drug,especially within 10 min after administration,should be highly vigilant and closely monitored.
基金Medical Health Science and Technology Project of Zhejiang Provincial Health Commission,China,No.2020372769.
文摘BACKGROUND Atezolizumab is a programmed death ligand 1(PD-L1)inhibitor,and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma(HCC).Treatment with immune checkpoint inhibitors(ICIs)can lead to hypersensitivity reactions;however,anaphylactic shock is rare.We present a case of life-threatening anaphylactic shock during atezolizumab infusion and performed a relevant literature review.CASE SUMMARY A 75-year-old man was diagnosed with HCC recurrence after hepatectomy.He was administered immunotherapy with atezolizumab plus bevacizumab after an allergy to a programmed death-1(PD-1)inhibitor.The patient showed a sudden onset of dizziness,numbness,and lack of consciousness with severe hypotension during atezolizumab infusion.The treatment was stopped immediately.The patient’s symptoms resolved after 5 mg dexamethasone was administered.Because of repeated hypersensitivity reactions to ICIs,treatment was changed to oral targeted regorafenib therapy.CONCLUSION Further research is necessary for elucidating the hypersensitivity mechanisms and establishing standardized skin test and desensitization protocols associated with PD-1 and PD-L1 to ensure effective treatment with ICIs.
